Conclusion
Systemic bevacizumab is a promising long-term treatment for severe RRP,
with pediatric oncology playing an important role in patient care.
- Derkay CS, Bluher AE. Update on Recurrent Respiratory Papillomatosis.Otolaryngol Clin North Am. 2019;52(4):669-679.
doi:10.1016/j.otc.2019.03.011
- Buchinsky FJ, Valentino WL, Ruszkay N, et al. Age at diagnosis, but
not HPV type, is strongly associated with clinical course in recurrent
respiratory papillomatosis. PLoS One. 2019;14(6):e0216697.
Published 2019 Jun 13. doi:10.1371/journal.pone.0216697
- Garcia J, Hurwitz HI, Sandler AB, et al. Bevacizumab (Avastin®) in
cancer treatment: A review of 15 years of clinical experience and
future outlook. Cancer Treat Rev . 2020;86:102017.
doi:10.1016/j.ctrv.2020.102017
- Barone A, Rubin JB. Opportunities and challenges for successful use of
bevacizumab in pediatrics. Front Oncol . 2013;3:92. Published
2013 Apr 29. doi:10.3389/fonc.2013.00092
- Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose
sublesional bevacizumab (avastin) for pediatric recurrent respiratory
papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214-221.
doi:10.1177/0003489414522977
- Zeitels SM, Lopez-Guerra G, Burns JA, Lutch M, Friedman AM, Hillman
RE. Microlaryngoscopic and office-based injection of bevacizumab
(Avastin) to enhance 532-nm pulsed KTP laser treatment of glottal
papillomatosis. Ann Otol Rhinol Laryngol Suppl. 2009;201:1-13.
doi:10.1177/000348940911800901
- Rogers DJ, Ojha S, Maurer R, Hartnick CJ. Use of adjuvant
intralesional bevacizumab for aggressive respiratory papillomatosis in
children. JAMA Otolaryngol Head Neck Surg . 2013;139(5):496-501.
doi:10.1001/jamaoto.2013.1810
- Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent
respiratory papillomatosis: A national survey. Laryngoscope .
2017;127(10):2225-2229. doi:10.1002/lary.26662.
- Mohr M, Schliemann C, Biermann C, et al. Rapid response to systemic
bevacizumab therapy in recurrent respiratory papillomatosis.Oncol Lett . 2014;8(5):1912-1918. doi:10.3892/ol.2014.2486
- Zur KB, Fox E. Bevacizumab chemotherapy for management of pulmonary
and laryngotracheal papillomatosis in a child. Laryngoscope .
2017;127(7):1538-1542. doi:10.1002/lary.26450
- Carnevale C, Ferrán-De la Cierva L, Til-Pérez G, et al. Safe use of
systemic bevacizumab for respiratory recurrent papillomatosis in two
children. Laryngoscope . 2019;129(4):1001-1004.
doi:10.1002/lary.27674
- Hamdi O, Dome J, Zalzal G, Preciado D. Systemic bevacizumab for
end-stage juvenile recurrent respiratory papillomas: A case report.Int J Pediatr Otorhinolaryngol. 2020;128:109706.
doi:10.1016/j.ijporl.2019.109706.
- Ruiz R, Balamuth N, Javia LR, Zur KB. Systemic Bevacizumab Treatment
for Recurrent Respiratory Papillomatosis: Long-Term Follow-Up
[published online ahead of print, 2022 Jan 19].Laryngoscope . 2022;10.1002/lary.30021. doi:10.1002/lary.30021
- Benedict JJ, Derkay CS. Recurrent respiratory papillomatosis: A 2020
perspective. Laryngoscope Investig Otolaryngol .
2021;6(2):340-345. Published 2021 Mar 13. doi:10.1002/lio2.545.
- Krstić, M., Pavlović, J., Stanković, P., & Milenković, T. (2014).
Etiopathogenesis of recurrent laryngeal papillomatosis and
contemporary treatment strategies. Acta medica Medianae, 53(4),
64-74.
- Rahbar R, Vargas SO, Folkman J, et al. Role of vascular endothelial
growth factor-A in recurrent respiratory papillomatosis. Ann
Otol Rhinol Laryngol . 2005;114(4):289-295.
doi:10.1177/000348940511400407
- Enrique OH, Eloy SH, Adrian TP, Perla V. Systemic bevacizumab as
adjuvant therapy for recurrent respiratory papillomatosis in children:
A series of three pediatric cases and literature review. Am J
Otolaryngol . 2021;42(5):103126. doi:10.1016/j.amjoto.2021.103126
- Allen CT. Biologics for the Treatment of Recurrent Respiratory
Papillomatosis. Otolaryngol Clin North Am . 2021;54(4):769-777.
doi:10.1016/j.otc.2021.05.002
- Thomas M, Thatcher N, Goldschmidt J, Ohe Y, McBride HJ, Hanes V.
Totality of evidence in the development of ABP 215, an approved
bevacizumab biosimilar. Immunotherapy . 2019;11(15):1337-1351.
doi:10.2217/imt-2019-0125
- Sidell DR, Balakrishnan K, Best SR, et al. Systemic Bevacizumab for
Treatment of Respiratory Papillomatosis: International Consensus
Statement. Laryngoscope . 2021;131(6):E1941-E1949.
doi:10.1002/lary.29343